Presentation

Company Profile
XVIVO Perfusion is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. XVIVO was founded in 1998 and is headquartered in Gothenburg, Sweden.

Recent highlights
Net sales increased organically in local currencies by 82% to SEK 59m (30m). Non-durable goods amounted to SEK 56.0m (28) in Q2, corresponding to an increase of 101% in SEK and 124% in local currency. The impact of the pandemic on hospitals varied between countries, with US seeing a recovery with the number of transplants for all major organs increasing sharply in 2021, exceeding 2019´s numbers. Adjusted EBITDA amounted to SEK 8,4m (-0.9), corresponding to a margin of 14% (-3%). XVIVO’s studies for PrimECC® and Heart preservation continued, and Xvivo is planning to add several European centres in the Heart preservation trial.

Outlook
In its Q2 report, XVIVO presented some strategic objectives for Q3-Q4: Launch 2022-2026 strategic plan, launch Kidney Assist Transport in the US, FDA submission for Liver Assist, speeding up the Heart Preservation and PrimECC clinical trials and increase reimbursement focus in Europe.